Novartis whips up flu vaccine quickly; Biogen, Genentech, GSK feud over anti-CD20 tech;

@FierceBiotech: PPD's BioDuro opens Shanghai discovery lab. FierceCRO story | Follow @FierceBiotech

@JohnCFierce: Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Report | Follow @JohnCFierce

@RyanMFierce: PTC, bluebird join the IPO frenzy in biotech with genetic therapies. Story | Follow @RyanMFierce

> Novartis ($NVS) readied a vaccine against a new strain of flu in days. Article

> Stemline Therapeutics ($STML) and Cyclacel Pharmaceuticals ($CYCC) announced follow-on financings worth a combined $80 million. Brief

> Aridis Pharmaceuticals has scooped up antibody assets and tech from Kenta Biotech. Item

> It's another turn of the screw in an ongoing legal battle of Biogen Idec ($BIIB) and Genentech versus GlaxoSmithKline ($GSK) over intellectual property for anti-CD20 antibodies. Biogen and Genentech requested a rehearing of the case. Release

Medical Device News

@FierceMedDev: Shorter Tryton side branch stent wins CE mark. Article | Follow @FierceMedDev

@MarkHFierce: J&J is leaving the metal hip replacement business behind. Bloomberg broke a good one: Report | Follow @MarkHFierce

 @DamianFierce: Quest buys Humana's toxicology and clinical lab business. News | Follow @DamianFierce

> Thoratec wins FDA nod for HeartMate controller. Report

> Thermedical scores $5.5M in funding for tumor, heart ablation research. Item

> Vascular Solutions sues Boston Scientific for 'blatant' patent infringement. News

Pharma News

 @FiercePharma: Another pharma deal: Sweden's Recipharm mulls IPO or partial sale, Reuters says. UBS advising. News | Follow @FiercePharma

 @EricPFierce: EMA committee backs Bayer's Diane-35 birth control drug, even as off-label acne treatment. Article | Follow @EricPFierce

> Sanofi, France remain at odds over fate of 600 R&D jobs. Article

> India sets controversial price caps on 650 drugs. Story

> GSK tries novel approach in emerging markets: price cuts. Report

And Finally… 23andMe CEO Anne Wojcicki grabs the attention of a VC crowd by telling them of their higher-than-average chances of going bald. Blog

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.